US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Zealand Pharma

< Previous 1 2 3 4 5 6 Next >
News headline image
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Half of 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Quarter of 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the Full Year 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
From Zealand Pharma
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
From Zealand Pharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >